Michele Novella
Nurse Practitioner · Danbury, CTNPI 1750307948
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 45.9% of the total. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,133 payments — averaging $291.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$152K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105K
- E.r. Squibb & Sons, L.L.C.$25K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Alkermes, Inc.$7K
- Biogen$6K
- plus $24K from 26 others
What the payments were for
- Consulting fees$94,03728%
- Speaking & faculty fees$148,02145%
- Travel & lodging$66,13120%
- Food & beverage$22,1287%
- Education$2420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$330,559 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $32,366 |
| CaplytaLumateperone Tosylate | 12 | $19,178 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $17,195 |
| TrintellixVortioxetine Hydrobromide | 11 | $12,311 |
| Lisdexamfetamine Dimesylate | 30 | $4,992 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 43 | $2,285 |
| Trazodone Hcl | 26 | $1,331 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $1,246 |
| Alprazolam ErAlprazolam | 13 | $560 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $419 |
| Zolpidem Tartrate | 17 | $417 |
| Bupropion XlBupropion Hcl | 12 | $271 |
| Clonazepam | 15 | $193 |
| Alprazolam | 24 | $60 |
| Lorazepam | 13 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,017 | $32,36611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $11,641 | $29,50642 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $105,030 | $19,17812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.
Other nurse practitioner in Danbury
- Jillian PhilbinDanbury$9K
- Amanda FuscoDanbury$9K
- Gloria NardellaDanbury$7K
- Lindita VincaCheshire$427K
- Catherine MilnePlymouth$361K
- Tiffany RydzNewtown$49K
- Paul FidrychNorwich$23K
- Priscilla QuilterNorwich$21K
- Kimberly BoldonMiddletown$19K
- Emma RobinsonStamford$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.